Please use this identifier to cite or link to this item:
Title: A facile synthesis of <i style="">N</i>-phenyl-6-hydroxy-3-bromo-4-arylazo quinolin-2-ones under phase transfer catalytic conditions and studies on their antimicrobial activities
Authors: Sharma, Pratibha
Kumar, Ashok
Pandey, Priti
Keywords: Arylazo quinoline
phase transfer catalysis
antimicrobial activities
Issue Date: Sep-2006
Publisher: CSIR
Series/Report no.: Int.Cl.<sup>8</sup> C07D
Abstract: The synthesis and characterization of <i style="">N</i>-phenyl-6-hydroxy-3-bromo-4-arylazoquinolin-2-ones has been reported under phase transfer catalytic conditions in 70% yields. Interaction of <i style="">N</i>-phenyl-2,5-dihydroxy-3-arylazo indoles with dibromocarbene under phase transfer catalysis conditions at 50-60<sup>o</sup>C and 600 r.p.m. results in a cycloaddition of the <i style="">in situ</i> generated carbene to the C=C bond followed by skeletal rearrangement in the indole frame work to yield quinoline nuclei. The structure of the compounds are established on the basis of their elemental, IR and <sup>1</sup>H NMR and <sup>13</sup>C NMR data. All the synthesized compounds have been evaluated for their <i style="">in vitro</i> growth inhibitory activity against <i style="">Escherichia coli</i>, <i style="">Pseudomonas diminuta, Bascillus subtilis, Bacillus megaterium</i> and <i style="">Staphylococcus aureus</i>. All the compounds show significant antibacterial activity. A perusal of data reveals that molecular refractive index (M<sub>R</sub>) is correlated linearly to the drug activity. The synthesized compounds have been subjected to acute toxicity studies to find out LD<sub>50</sub> values. The compounds do not show any toxicity up to dose of 7.5 mg/kg body weights in rats.
Description: 2077-2082
ISSN: 0975-0983(Online); 0376-4699(Print)
Appears in Collections:IJC-B Vol.45B(09) [September 2006]

Files in This Item:
File Description SizeFormat 
IJCB 45B(9) 2077-2082.pdf65.19 kBAdobe PDFView/Open

Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.